Filing Flows › Ultragenyx Pharmaceutical (RARE) › Q3 2026 › vs Q2 2026
Ultragenyx Pharmaceutical (RARE) Q3 2026 vs Q2 2026 (quarter over quarter)
Ultragenyx Pharmaceutical's revenue fell $41.0M (-19%) from $214M in Q2 2026 to $173M in Q3 2026. The biggest changes: Royalty −$34.0M (-33%); Product −$7.0M (-6%).
Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product | $105M | $112M | −$7.0M | -6% |
| Royalty | $68.0M | $102M | −$34.0M | -33% |
| Revenue | $173M | $214M | −$41.0M | -19% |
| Income tax benefit | $9.0M | −$1.0M | $10.0M | — |
| Net loss | $118M | $92.0M | $26.0M | +28% |
| Costs & expenses | $300M | $306M | −$6.0M | -2% |
| Operating costs | $283M | $289M | −$6.0M | -2% |
| Interest & other, net | $17.0M | $16.0M | $1.0M | +6% |
| Research & development | $154M | $167M | −$13.0M | -8% |
| SG&A | $97.0M | $88.0M | $9.0M | +10% |
| Other operating costs | $32.0M | $34.0M | −$2.0M | -6% |
| Operating cash sources | $118M | $92.0M | $26.0M | +28% |
| Depreciation & amortization | $9.0M | $8.0M | $1.0M | +12% |
| Share-based compensation | $34.0M | $34.0M | $0 | 0% |
| Working capital & other | $32.0M | −$47.0M | $79.0M | — |
| Cash used in operations | $43.0M | $97.0M | −$54.0M | -56% |
| Net loss absorbed | $118M | $92.0M | $26.0M | +28% |
Questions
How much did Ultragenyx Pharmaceutical's revenue grow quarter over quarter in Q3 2026?
Ultragenyx Pharmaceutical's revenue fell $41.0M (-19%) from $214M in Q2 2026 to $173M in Q3 2026.
What drove Ultragenyx Pharmaceutical's revenue change in Q3 2026?
Royalty −$34.0M (-33%); Product −$7.0M (-6%).